The Netherlands
CimCure B.V., founded in 2016, is a pioneering company in the Health Care industry, headquartered in The Netherlands. Specializing in cancer immunotherapy, CimCure B.V. is focused on developing vaccination-based therapies targeting the blood vessels of solid tumors, a common characteristic in most cases.
Operating under the slogan "Cancer immunotherapy for solid tumors," the company's innovative approach aims to transform cancer treatment paradigms. Their promising research and development efforts have already garnered significant attention from the investment community.
In a testament to its potential, CimCure B.V. secured a €5.00M Seed Round investment on 07 June 2022, with backing from reputable investors such as Positron Ventures and industry expert Tom Würdinger. This financial boost is poised to accelerate their pipeline and potentially revolutionize therapies for solid tumors.
